PT - JOURNAL ARTICLE AU - Kalamkar, Saurabh AU - Acharya, Jhankar AU - Madathil, Arjun Kolappurath AU - Gajjar, Vijay AU - Divate, Uma AU - Karandikar-Iyer, Sucheta AU - Goel, Pranay AU - Ghaskadbi, Saroj TI - Randomised clinical trial of long term glutathione supplementation offers protection from oxidative damage, improves HbA1c in elderly type 2 diabetic patients AID - 10.1101/2021.04.27.21256157 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.27.21256157 4099 - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21256157.short 4100 - http://medrxiv.org/content/early/2021/04/29/2021.04.27.21256157.full AB - Sustained hyperglycemia in type 2 diabetes is associated with low levels of the endogenous antioxidant glutathione (GSH), which leads to oxidative stress and tissue damage. It is therefore important to investigate whether oral GSH supplementation would restore GSH levels, and also help improve redox state and glycaemia in diabetic individuals. We conducted a pragmatic clinical trial to assess effectiveness of oral GSH supplementation along with anti-diabetic treatment. 104 non-diabetic and 250 diabetic individuals were recruited. All the 250 diabetic individuals were on anti-diabetic therapy; of these 125 were given oral GSH supplementation additionally for a period of six months. Fasting and PP glucose and insulin, HbA1c, GSH and the oxidative DNA damage marker 8-OHdG were measured at the recruitment time and after three and six months of supplementation. GSH supplementation increased blood GSH and decreased 8-OHdG significantly within three months in diabetic individuals. It also reduced HbA1c within three months and stabilized it thereafter in diabetic population overall. Patients above 55 years benefited more as evidenced by a significant decrease in HbA1c and 8-OHdG and an increase in fasting insulin. Data suggest that GSH supplementation can be used as an adjunct therapy to anti-diabetic treatment to achieve better glycemic targets, especially in elderly population.Trial registered This study has been registered with Clinical Trials Registry-India (CTRI/2018/01/011257)Novelty bulletsOral GSH supplementation replenishes body stores of GSH and significantly reduces oxidative DNA damage in diabetic patients over six months.HbA1c is lowered at three months and is stabilized thereafter.A significant decrease in HbA1c and elevated fasting insulin was observed in people older than 55 years.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialCTRI/2018/01/011257 (Clinical Trials Registry-India)Funding StatementThis work was financially supported by XIIth Plan-Innovation Grant (University Grants Commission (UGC), Savitribai Phule Pune University, Pune. We also acknowledge partial financial support from UGC-Centre for Advanced Studies (CAS) and Department of Science and Technology-Promotion of University Research and Scientific Excellence (PURSE) program of the Department of Zoology, Savitribai Phule Pune University. SK is a recipient of a Junior Research fellowship from the Council of Scientific and Industrial Research (CSIR), India. AK is financially supported by DST Inspire, Government of India.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Ethical Committee of Jehangir Hospital Development Center, Pune (Dr. Ravindra Ghooi, Chairman, Ethics committee Jehangir clinical development center ECN- ECR/352/Inst/NIH/2013); Institutional Biosafety Committee of SPPU (Bot/27A/15), Pune; and Institutional Ethical Committee of IISER, Pune. Signed informed consent was obtained from all the subjects at the time of enrollment in the study after explaining the purpose and nature of the study. All participants in this study were de-identified using a numbered code. This study is registered with Clinical Trials Registry-India (CTRI/2018/01/011257).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.